Who’s Hired? ANI Names New CEO

ANI Pharmaceuticals Picks New Chief As Teva and Mylan Make Moves

ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.

Team_Leader
ANI Pharmaceuticals has selected a new leader • Source: Shutterstock

ANI Pharmaceuticals has named Cipla USA chief executive Nikhil Lalwani to become its new president and CEO from 8 September. Lalwani – who will join ANI’s board on the same date – will replace interim president and CEO Patrick Walsh, who had stepped in after the departure of former chief Arthur Przybyl earlier this year. (Also see "ANI Names Interim CEO As Przybyl Prepares To Step Down" - Generics Bulletin, 8 May, 2020.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Generics Bulletin

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By 

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By 

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By 

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.